The role of MRI and PET/SPECT in Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 6, Issue 6, 2006, Pages 629-647

  Coimbra, Alexandre ^a   Williams, Donald S ^a   Hostetler, Eric D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's; Amyloid; Atrophy; Biomarker; Imaging; MRI; PET; SPECT

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINESTERASE; ACRIDINE ORANGE; AMYLOID BETA PROTEIN; BENZENE DERIVATIVE; BENZOXAZOLE DERIVATIVE; BIOLOGICAL MARKER; CHOLINE; CONGO RED; CREATINE; CREATINE PHOSPHATE; FLAVONE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INOSITOL; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PHOSPHORYLCHOLINE; PUTRESCINE; PYRIDINE DERIVATIVE; THIOFLAVINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN REGION; CELL ACTIVATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DRUG STRUCTURE; DRUG UPTAKE; EARLY DIAGNOSIS; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; MEDICAL ASSESSMENT; MICROGLIA; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; RAT; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDITY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SENILE PLAQUES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33646197921     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776743075     Document Type: Review

References (171)

1. Pietrzik, C.; Behl, C. Concepts for the Treatment of Alzheimer's Disease: Molecular Mechanisms and Clinical Application. Int. J. Exp. Path. 2005, 86, 173-185.
2. Grossberg, G. T. Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease: Getting On and Staying On. Curr. Therap. Res. 2003, 64, 216-235.
3. Mosconi, L. Brain Glucose Metabolism in the Early and Specific Diagnosis of Alzheimer's Disease. Eur. J. Nucl. Med. Mol. Imag. 2005, 32, 486-510.
4. Burns, H. D.; Hamill, T. G.; Eng, W.; Francis, B.; Fioravanti, C., Gibson, R. Positron Emission Tomography Neuroreceptor Imaging as a Tool in Drug Discovery, Research and Development. Curr. Op. Chem. Biol. 1999, 3, 388-394.
5. Schmidt B.; Braun, H. A.; Narlawar, R. Drug Development and PET-Diagnostics for Alzheimer's Disease. Curr. Med. Chem. 2005, 12, 1677-1695.
6. Lee, B. C. J.; Mintun, M.; Buckner, R. L.; Morris, J. C. Imaging of Alzheimer's Disease. J. Neuroimaging 2003, 13, 199-214.
7. Masdeu, J. C.; Zubieta, J. L.; Arbizu, J. Neuroimaging as a Marker of the Onset and Progression of Alzheimer's Disease. J. Neuro. Sci. 2005, 236, 55-64.
8. Gomez-Isla, T.; Price, J. L.; McKeel, D. W., Jr.; Morris, J. C.; Growdon, J. H.; Hyman, B. T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996, 16, 4491-4500.
9. Price, J. L.; Ko, A. I.; Wade, M. J.; Tsou, S. K.; McKeel, D. W.; Morris, J. C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001, 58, 1395-1402.
10. Simic, G.; Kostovic, I.; Winblad, B.; Bogdanovic, N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J. Comp. Neurol. 1997, 379, 482-494.
11. Zarow, C.; Vinters, H. V.; Ellis, W. G.; Weiner, M. W.; Mungas, D.; White, L.; Choi, H. C. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann. Neurol. 2005, 57, 896-903.
12. Brun, A.; Englund, E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 1986, 19, 253-262.
13. Alzheimer's Association Neuroimaging Work Group, A. A. The Use of MRI and PET for Clinical Diagnosis of Dementia and Investigation of Cognitive Impairment: A Consensus Report. http://vwwalzorg/Research/Papers/Imaging_consensus_reportpdf 2004.
14. Jack, C. R., Jr.; Dickson, D. W.; Parisi, J. E.; Xu, Y. C.; Cha, R. H.; O'Brien, P. C.; Edland, S. D.; Smith, G. E.; Boeve, B. F.; Tangalos, E. G.; Kokmen, E.; Petersen, R. C. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58, 750-757.
15. Jack, C. R., Jr.; Slomkowski, M.; Gracon, S.; Hoover, T. M.; Felmlee, J. P.; Stewart, K.; Xu, Y.; Shiung, M.; O'Brien, P. C.; Cha, R.; Knopman, D.; Petersen, R. C. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003, 60, 253-260.
16. Jack, C. R., Jr.; Shiung, M. M.; Gunter, J. L.; O'Brien, P. C.; Weigand, S. D.; Knopman, D. S.; Boeve, B. F.; Ivnik, R. J.; Smith, G. E.; Cha, R. H.; Tangalos, E. G.; Petersen, R. C. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62, 591-600.
17. Mungas, D.; Harvey, D.; Reed, B. R.; Jagust, W. J.; DeCarli, C.; Beckett L.; Mack, W. J.; Kramer, J. H.; Weiner, M. W.; Schuff, N.; Chui, H. C. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005, 65, 565-571.
18. Chetelat, G.; Baron, J. C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003, 18, 525-541.
19. Teipel, S. J.; Bayer, W.; Alexander, G. E.; Bokde, A. L.; Zebuhr, Y.; Teichberg, D.; Muller-Spahn, F.; Schapiro, M. B.; Moller, H. J.; Rapoport, S. I.; Hampel, H. Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol. Aging 2003, 24, 85-94.
20. Petersen, R. C.; Jack, C. R., Jr.; Xu, Y. C.; Waring, S. C.; O'Brien, P. C.; Smith, G. E.; Ivnik, R. J.; Tangalos, E. G.; Boeve, B. F.; Kokmen, E. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000, 54, 581-587.
21. Thompson, P. M.; Hayashi, K. M.; de Zubicaray, G.; Janke, A. L.; Rose, S. E.; Semple, J.; Herman, D.; Hong, M. S.; Dittmer, S. S.; Doddrell, D. M.; Toga, A. W. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 2003, 23, 994-1005.
22. Karas, G. B.; Scheltens, P.; Rombouts, S. A.; Visser, P. J.; van Schijndel, R. A.; Fox, N. C.; Barkhof, F. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004, 23, 708-716.
23. Karas, G. B.; Burton, E. J.; Rombouts, S. A.; van Schijndel, R. A.; O'Brien, J. T.; Scheltens, P.; McKeith, L G.; Williams, D.; Ballard, C.; Barkhof, F. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage 2003, 18, 895-907.
24. Hirata, Y.; Matsuda, H.; Nemoto, K.; Ohnishi, T.; Hirao, K.; Yamashita, F.; Asada, T.; Iwabuchi, S.; Samejima, H. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci. Lett. 2005, 382, 269-274.
25. Chan, D.; Janssen, J. C.; Whitwell, J. L.; Watt, H. C.; Jenkins, R.; Frost, C.; Rossor, M. N.; Fox, N. C. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003, 362, 1121-1122.
26. Jack, C. R., Jr.; Petersen, R. C.; Xu, Y.; O'Brien, P. C.; Smith, G. E.; Ivnik R. J.; Tangalos, E. G.; Kokmen, E. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998, 51, 993-999.
27. Jack, C. R., Jr.; Petersen, R. C.; Xu, Y.; O'Brien, P. C.; Smith, G. E.; Ivnik, R. J.; Boeve, B. F.; Tangalos, E. G.; Kokmen, E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000, 55, 484-489.
28. Du, A. T.; Schuff, N.; Kramer, J. H.; Ganzer, S.; Zhu, X, P.; Jagust, W. J.; Miller, B. L.; Reed, B. R.; Mungas, D.; Yaffe, K.; Chui, H. C.; Weiner, M. W. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 2004, 62, 422-427.
29. Du, A. T.; Schuff, N.; Amend, D.; Laakso, M. P.; Hsu, Y. Y.; Jagust, W. J.; Yaffe, K.; Kramer, J. H.; Reed, B.; Norman, D.; Chui, H. C.; Weiner, M. W. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2001, 71, 441-447.
30. Fox, N. C.; Cousens, S.; Scahill, R.; Harvey, R. J.; Rossor, M. N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 2000, 57, 339-344.
31. Chan, D.; Fox, N. C.; Jenkins, R.; Scahill, R. I.; Crum, W. R.; Rossor, M. N. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001, 57, 1756-1763.
32. Chen, C. C.; Wan, Y. L.; Wai, Y. Y.; Liu, H. L. Quality assurance of clinical MRI scanners using ACR MRI phantom: preliminary results. J. Digit. Imaging 2004, 17, 279-284.
33. Firbank, M. J.; Harrison, R. M.; Williams, E. D.; Coulthard, A. Quality assurance for MRI: practical experience. Br. J. Radiol. 2000, 73, 376-383.
34. Lewis, E. B.; Fox, N. C. Correction of differential intensity inhomogeneity in longitudinal MR images. Neuroimage 2004, 23, 75-83.
35. Carmichael, O. T.; Aizenstein, H. A.; Davis, S. W.; Becker, J. T.; Thompson, P. M.; Meltzer, C. C.; Liu, Y. Atlas-based hippocampus segmentation in Alzheimer's disease and mild cognitive impairment. Neuroimage 2005, 27, 979-990.
36. Freeborough, P. A.; Fox, N. C. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med. Imaging 1997, 16, 623-629.
37. Fox, N. C.; Freeborough, P. A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J. Magn. Reson. Imaging 1997, 7, 1069-1075.
38. Ashburner, J.; Friston, K. J. Voxel-based morphometry-the methods. Neuroimage 2000, 11, 805-821.
39. Good, C. D.; Scahill, R. I.; Fox, N. C.; Ashburner, J.; Friston, K. J.; Chan, D.; Crum, W. R.; Rossor, M. N.; Frackowiak, R. S. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002, 17, 29-46.
40. Liang, Z.-P.; Lauterbur, P. C. Principles of magnetic resonance imaging: a signal processing perspective; IEEE Press: New York, 1999.
41. Wheeler-Kingshott, C. A.; Barker, G. J.; Steens, S. C.; Buchem, M. A. v. D: the Diffusion of Water. Quantitative MRI of the Brain; John Wiley & Sons Ltd: Chippenham, England, 2003; pp 203-256.
42. Pierpaoli, C.; Basser, P. J. Toward a quantitative assessment of diffusion anisotropy. Magn. Reson. Med. 1996, 36, 893-906.
43. Pierpaoli, C.; Jezzard, P.; Basser, P. J.; Barnett, A.; Di Chiro, G. Diffusion tensor MR imaging of the human brain. Radiology 1996, 201, 637-648.
44. Basser, P. J.; Pierpaoli, C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B 1996, 111, 209-219.
45. Song, S. K.; Kim, J. H.; Lin, S. J.; Brendza, R. P.; Holtzman, D. M. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis. 2004, 15, 640-647
46. Sun, S. W.; Song, S. K.; Harms, M. P.; Lin, S. J.; Holtzman, D. M.; Merchant, K. M.; Kotyk, J. J. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp. Neurol. 2005, 191, 77-85.
47. Kingsley, P. B.; Monahan, W. G. Contrast-to-noise ratios of diffusion anisotropy indices. Magn. Reson. Med. 2005, 53, 911-918.
48. Takahashi, S.; Yonezawa, H.; Takahashi, J.; Kudo, M.; Inoue, T.; Tohgi, H. Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging. Neurosci. Lett. 2002, 332, 45-48.
49. Rose, S. E.; Chen, F.; Chalk, J. B.; Zelaya, F. O.; Strugnell, W. E.; Benson, M.; Semple, J.; Doddrell, D. M. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J. Neurol. Neurosurg. Psychiatry 2000, 69, 528-530.
50. Yoshiura, T.; Mihara, F.; Ogomori, K.; Tanaka, A.; Kaneko, K.; Masuda, K. Diffusion tensor in posterior cingulate gyrus: correlation with cognitive decline in Alzheimer's disease. Neuroreport 2002, 13, 2299-2302.
51. Head, D.; Buckner, R. L.; Shimony, J. S.; Williams, L. E.; Akbudak, E.; Conturo, T. E.; McAvoy, M.; Morris, J. C.; Snyder, A. Z. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb. Cortex 2004, 14, 410-423.
52. Bozzali, M.; Falini, A.; Franceschi, M.; Cercignani, M.; Zuffi, M.; Scotti, G.; Comi, G.; Filippi, M. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 2002, 72, 742-746.
53. Nusbaum, A. O.; Tang, C. Y.; Buchsbaum, M. S.; Wei, T. C.; Atlas, S. W. Regional and global changes in cerebral diffusion with normal aging. Am. J. Neuroradiol. 2001, 22, 136-142.
54. Han, X.; Holtzman, D. M.; McKeel, D. W., Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 2001, 77, 1168-1180.
55. Han, X.; D, M. H.; McKeel, D. W., Jr.; Kelley, J.; Morris, J. C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82, 809-818.
56. Xu, J.; Chen, S.; Ahmed, S. H.; Chen, H.; Ku, G.; Goldberg, M. P.; Hsu, C. Y. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci. 2001, 21, RC118.
57. Lee, J. T.; Xu, J.; Lee, J. M.; Ku, G.; Han, X.; Yang, D. I.; Chen, S.; Hsu, C. Y. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell. Biol. 2004, 164, 123-131.
58. Bronge, L.; Bogdanovic, N.; Wahlund, L. O. Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement. Geriatr. Cogn. Disord. 2002, 13, 205-212.
59. Bronge, L.; Wahlund, L. O. Prognostic significance of white matter changes in a memory clinic population. Psychiatry Res. 2003, 122, 199-206.
60. Scheltens, P.; Barkhof, F.; Fazekas, F. White-matter changes on MRI as surrogate marker. Int. Psychogeriatr. 2003, 15 Suppl. 1, 261-265.
61. Englund, E.; Sjobeck, M.; Brockstedt, S.; Latt, J.; Larsson, E. M. Diffusion tensor MRI post mortem demonstrated cerebral white matter pathology. J. Neurol. 2004, 251, 350-352.
62. Pfefferbaum, A.; Adalsteinsson, E.; Sullivan, E. V. Replicability of diffusion tensor imaging measurements of fractional anisotropy and trace in brain. J. Magn. Reson. Imaging 2003, 18, 427-433.
63. Chen, J. G.; Charles, H. C.; Barboriak, D. P.; Doraiswamy, P. M. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol. Scand. Suppl. 2000, 176, 20-26.
64. Rudkin, T. M.; Arnold, D. L. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch. Neurol. 1999, 56, 919-926.
65. Valenzuela, M. J.; Sachdev, P. Magnetic resonance spectroscopy in AD. Neurology 2001, 56, 592-598.
66. Arnold, D. L. Magnetic resonance spectroscopy: imaging axonal damage in MS. J. Neuroimmunol. 1999, 98, 2-6.
67. Miller, B. L.; Chang, L.; Booth, R.; Ernst, T.; Comford, M.; Nikas, D.; McBride, D.; Jenden, D. J. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996, 58, 1929-1935.
68. Ross, B. D. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 1991, 4, 59-63.
69. Falini, A.; Bozzali, M.; Magnani, G.; Pero, G.; Gambini, A.; Benedetti, B.; Mossini, R.; Franceschi, M.; Comi, G.; Scotti, G.; Filippi, M. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 2005, 26, 1159-1163.
70. Rai, G. S.; McConnell, J. R.; Waldman, A.; Grant, D.; Chaudry, M. Brain proton spectroscopy in dementia: an aid to clinical diagnosis. Lancet 1999, 353, 1063-1064.
71. Moats, R. A.; Ernst, T.; Shonk, T. K.; Ross, B. D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 1994, 32, 110-115.
72. Parnetti, L.; Lowenthal, D. T.; Presciutti, O.; Pelliccioli, G. P.; Palumbo, R.; Gobbi, G.; Chiarini, P.; Palumbo, B.; Tarducci, R.; Senin, U. IH-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheirner's disease. J. Am. Geriatr. Soc. 1996, 44, 133-138.
73. Kantarci, K.; Jack, C. R., Jr.; Xu, Y. C.; Campeau, N. G.; O'Brien, P. C.; Smith, G. E.; Ivnik, R. J.; Boeve, B. F.; Kokmen, E.; Tangalos, E. G.; Petersen, R. C. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000, 55, 210-217.
74. Parnetti, L.; Tarducci, R.; Presciutti, O.; Lowenthal, D. T.; Pippi, M.; Palumbo, B.; Gobbi, G.; Pelliccioli, G. P.; Senin, U. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech. Aging Dev. 1997, 97, 9-14.
75. Jessen, F.; Block, W.; Traber, F.; Keller, E.; Flacke, S.; Papassotiropoulos, A.; Lamerichs, R.; Heun, R.; Schild, H. H. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000, 55, 684-688.
76. Schuff, N.; Capizzano, A. A.; Du, A. T.; Amend, D. L.; O'Neill, J.; Norman, D.; Kramer, J.; Jagust, W.; Miller, B.; Wolkowitz, O. M.; Yaffe, K.; Weiner, M. W. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002, 58, 928-935.
77. Klunk, W. E.; Xu, C.; Panchalingam, K.; McClure, R. J.; Pettegrew, J. W. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 1996, 17, 349-357.
78. Mohanakrishnan, P.; Fowler, A. H.; Vonsattel, J. P.; Husain, M. M.; Jolles, P. R.; Liem, P.; Komoroski, R. A. An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp. Brain Res. 1995, 102, 503-510.
79. Pettegrew, J. W.; Kopp, S. J.; Minshew, N. J.; Glonek, T.; Feliksik, J. M.; Tow, J. P.; Cohen, M. M. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J Neuropathol. Exp. Neurol. 1987, 46, 419-430.
80. Pettegrew, J. W.; Moossy, J.; Withers, G.; McKeag, D.; Panchalingam, K. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol. Exp. Neurol. 1988, 47, 235-248.
81. Gonzalez, R. G.; Guimaracs, A. R.; Moore, G. J.; Crawley, A.; Cupples, L. A.; Growdon, J. H. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1996, 10, 46-52.
82. Murphy, D. G.; Bottomley, P. A.; Salerno, J. A.; DeCarli, C.; Mentis, M. J.; Grady, C. L.; Teichberg, D.; Giacometti, K. R.; Rosenberg, J. M.; Hardy, C. J.; et al. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch. Gen. Psychiatry 1993, 50, 341-349.
83. Bottomley, P. A.; Cousins, J. P.; Pendrey, D. L.; Wagle, W. A.; Hardy, C. J.; Eames, F. A.; McCaffrey, R. J.; Thompson, D. A. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology 1992, 183, 695-699.
84. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81, 741-766.
85. Selkoe, D. J. Imaging Alzheimer's amyloid. Nat. Biotechnol. 2000, 18, 823-824.
86. Benveniste, H.; Einstein, G.; Kim, K. R.; Hulette, C.; Johnson, G. A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonace microscopy. Proc. Natl. Acad. Sci. USA 1999, 96, 14079-14084.
87. Dhenain, M.; Privat, N.; Duyckaerts, C.; Jacobs, R. E. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed. 2002, 15, 197-203.
88. Helpern, J. A.; Lee, S. P.; Falangola, M. F.; Dyakin, V. V.; Bogart, A.; Ardekani, B.; Duff, K.; Branch, C.; Wisniewski, T.; de Leon, M. J.; Wolf, O.; O'Shea, J.; Nixon, R. A. MRI assessment of neuropathology in a trasgenic mouse model of Alzheimer's disease. Magn. Reson. Med. 2004, 51, 794-798.
89. Poduslo, J. F.; Wengenack, T. M.; Curran, G. L.; Wisniewski, T.; Sigurdsson, E. M.; Macura, S. I.; Borowski, B. J.; Jack, C. R., Jr. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11, 315-329.
90. Wadghiri, Y. Z.; Sigurdsson, E. M.; Sadowski, M.; Elliott, J. I.; Li, Y.; Scholtzova, H.; Tang, C. Y.; Aguinaldo, G.; Pappolla, M.; Duff, K.; Wisniewski, T.; Turnbull, D. H. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 2003, 50, 293-302
91. Jack, C. R.,Jr.; Garwood, M.; Wengenack, T. M.; Borowski, B.; Curran, G. L.; Lin, J.; Adriany, G.; Grohn, O. H.; Grimm, R.; Poduslo, J. F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52, 1263-1271.
92. Zhang, J.; Yarowsky, P.; Gordon, M. N.; Di Carlo, G.; Munireddy, S.; van Zijl, P. C.; Mori, S. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn. Reson. Med. 2004, 51, 452-457.
93. Higuchi, M.; Iwata, N.; Matsuba, Y.; Sato, K.; Sasamoto, K.; Saido, T. C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8, 527-533.
94. Jack, C. R., Jr.; Wengenack, T. M.; Reyes, D. A.; Garwood, M.; Curran, G. L.; Borowski, B. J.; Lin, J.; Preboske, G. M.; Holasek, S. S.; Adriany, G.; Poduslo, J. F. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25, 10041-10048.
95. Silverman, D. H. S.; Small, G. W.; Chang, C. Y.; Lu, C. S.; de Aburto, M. A. K.; Chen, W.; Czemin, J.; Rapoport, S. L.; Pietrini, P.; Alexander, G. E.; Schapiro, M. B.; Jagust, W. J.; Hoffman, J. M.; Welsh-Bohmer, K. A.; Alavi, A.; Clark, C. M.; Salmon, E.; DeLeon, M. J.; Mielke, R.; Cummings, J. L.; Kowell, A. P.; Gambhir, S. S.; Hoh, C. K.; Phelps, M. E. Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-Term Outcome. JAMA 2001, 286, 2120-2127.
96. Silverman, D. H. S. Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging. J. Nucl. Med. 2004, 45, 594-607.
97. Encinas, M.; de Juan, R.; Marcos, A.; Gil, P.; Barabash, A.; Fernandez, C.; de Ugarte, C.; Cabranes, J. A. Regional Cerebral Blood Flow Assessed with 99mTc-ECD SPET as a Marker of Progression of Mild Cognitive Impariment to Alzheimer's Disease. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1473-1480.
98. Jagust, W.; Thisted, R.; Devous, M. D.; Heertum, R. V.; Mayberg, H.; Jobst, K.; Smith, A. D.; Borys, N. SPECT Perfusion Imaging in the Diagnosis of Alzheimer's Disease. Neurology 2001, 56, 950-956.
99. Hardy, J. A.; Higgins, G. A. The Amyloid Cascade Hypothesis. Science 1992, 256, 184-185.
100. Bacskai, B. J.; Kajdasz, S. T.; Christie, R. H.; Carter, C.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B. T. Imaging of Amyloid-Beta Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy. Nat. Med. 2001, 7, 369-372.
101. Gibson, R. E.; Burns, H. D.; Hamill, T. G.; Eng, W.; Francis, B. E.; Ryan, C. Non-Invasive Radiotracer Imaging as a Tool for Drug Development Curr. Pharm. Des. 2000, 6, 973-989.
102. Passchier, J.; Gee, A.; Willemsen, A.; Vaalburg, W.; van Waarde, A. Measuring Drug-Related Receptor Occupancy with Positron Emmission Tomography. Methods 2002, 27, 278-286.
103. Zhuang, Z. P.; Kung, M. P.; Hou, C.; Skovronsky, D. M.; Gur, T. L.; Plossl, K.; Trojanowski, J. Q.; Lee, V. M.; Kong, H. F. Radioiodinated Styrylbenzenes and Thioflavins as Probes for Amyloid Aggregates. J. Med. Chem. 2001, 44, 1905-1914.
104. Klunk, W. E.; Wang, Y.; Huang, G. F.; Debnath, M. L.; Holt, D. P.; Shao, L.; Hamilton, R. L.; Ikonomovic, M. D.; DeKosky, S. T.; Mathis, C. A. The Binding of 2-(4′-methylaminophenyl) benzothiazole to Postmortem Brain Homogenates is Dominated by the Amyloid Component. J. Neurosci. 2003, 23, 2086-2092.
105. Waterhouse, R. N. Determination of Lipophilicity and Its Use as a Predictor of Molecular Imaging Agents. Mol. Imag. Biol. 2003, 5, 376-389.
106. Maggio, J. E.; Stimson, E. R.; Ghilardi, J. R.; Allen, C. J.; Dahl, C. E.; Whitcomb, D. C.; Vigna, S. R.; Vinters, H. V.; Labenski, M. E.; Mantyh, P. W. Reversible In Vitro Growth of Alzheimer Disease Beta-Amyloid Plaques by Deposition of Labeled Amyloid Peptide. Proc. Natl. Acad. Sci. U.S.A 1992, 89, 5462-5466.
107. Saito, Y.; Buciak, J.; Yang, J.; Pardridge, W. M. Vector-Mediated Delivery of 125I-Labeled Beta-Amyloid Peptide A Beta 1-40 Through the Blood-Brain Barrier and Binding to Alzheimer Disease Amyloid of the A Beta 1-40/Vector Complex. Proc. Natl. Acad. Sci. U.S.A 1995, 92, 10227-10231.
108. Friedland, R. P.; Shi, J.; Lamanna, J. C.; Smith, M. A.; Perry, G. Prospects for Noninvasive Imaging of Brain Amyloid Beta in Alzheimer's Disease. Ann. NY Acad. Sci. 2000, 903, 123-128.
109. Lovat, L. B.; O'Brien, A. A.; Armstrong, S. F.; Madhoo, S.; Bulpitt, C. J.; Rossor, M. N.; Pepys, M. B.; Hawkins, P. N. Scintigraphy with 123I-Serum Amyloid P Component in Alzheimer Disease. Alzheimer Des. Assoc. Disord. 1998, 12, 208-210.
110. Elhaddaoui, A.; Pigorsch, E.; Delacourte, A.; Turrell, S. Competition of Congo Red and Thioflavin S Binding to Amyloid Sites in Alzheimer's Diseased Tissue. Biospectroscopy 1995, 1, 351-356.
111. Styren, S. D.; Hamilton, R. L.; Styren, G. C.; Klunk, W. E. X-34, A Fluorescent Derivative of Congo Red: a Novel Histochemical Stain for Alzheimer's Disease Pathology. J. Histochem. Cytochem. 2000, 48, 1223-1232.
112. Skovronsky, D. M.; Zhang, B.; Kung, M. P.; Kong, H. F.; Trojanowski, J. Q.; Lee, V. M. In Vivo Detection of Amyloid Plaques in a Mouse Model of Alzheimer's Disease. Proc. Natl. Acad. Sci. USA 2000, 97, 7609-7614.
113. Klunk, W. E.; Bacskai, B. J.; Mathis, C. A.; Kajdasz, S. T.; McLellan, M. E.; Frosch, M. P.; Debnath, M. L.; Holt, D. P.; Wang, Y.; Hyman, B. T. Imaging Abeta Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. J Neuropathol Exp. Neurol. 2002, 61, 797-805.
114. Sair, H. I.; Doraiswamy, P. M.; Petrella, F. R. In Vivo Amyloid Imaging in Alzheimer's Disease. Neuroradiology 2004, 46, 93-104.
115. Shimadzu, H.; Suemoto, T.; Suzuki, M.; Shiomitsu, T.; Okamura, N.; Kudo, Y.; Sawada, T. A Novel Probe for Imaging Amyloid-Beta: Synthesis of F-18 Labelled BF-108, an Acridine Orange Analog. J. Label Compd. Radiopharm. 2003, 46, 765-772.
116. Klunk, W. E.; Wang, Y.; Huang, G. F.; Debnath, M. L.; Holt, D. P.; Mathis, C. A. Uncharged Thioflavin-T Derivatives Bind to Amyloid-Beta Protein with High Affinity and Readily Enter the Brain. Life Sci. 2001, 69, 1471-1484.
117. Zhuang, Z. P.; Kung, M. P.; Hou, C.; Plossl, K.; Skovronsky, D.; Gur, T. L.; Trojanowski, J. Q.; Lee, V. M.; Kong, H. F. IBOX(2-(4′-Dimethylaminophenyl)-6-Iodobenzoxazole): a Ligand for Imaging Amyloid Plaques in the Brain. Nuc. Med. Biol. 2001, 28, 887-894.
118. Cai, L.; Chim, F. T.; Pike, V. W.; Toyama, H.; Liow, J. S.; Zoghbi, S. S.; Modell, K.; Briard, E.; Shetty, H. U.; Sincleair, K.; Donohue, S.; Tipre, D.; Kung, M. P.; Dagostin, C.; Widdowson, D. A.; Green, M.; Gao, W.; Herman, M. M.; Ichise, M.; Innis, R. B. Synthesis and Evaluation of Two 18F-Labeled 6-Iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-alpyridine Derivatives as Prospective Radioligands for Beta-Amyloid in Alzbeimer's Disease. J. Med. Chem. 2004, 47, 2208-2218.
119. Zhuang, Z. P.; Kung, M. P.; Wilson, A.; Lee, C. W.; Plossl, K.; Hou, C.; Holzman, D. M.; Kung, H. F. Structure-Activity Relationship of Imidazo[1,2-alpha]pyridines as Ligands for Detecting Beta-Amyloid Plaques in the Brain. J. Med. Chem. 2003, 46, 237-243.
120. Ono, M.; Kung, M. P.; Hou, C.; Kung, H. F. Benzofuran Derivatives as Abeta-Aggregate-Specific Imaging Agents for Alzheimer's Disease. Nuc. Med. Biol. 2002, 29, 633-642.
121. Kung, M. P.; Hou, C.; Zhuang, Z. P.; Zhang, B.; Skovronsky, D.; Trojanowski, J. Q.; Lee, V. M.; Kung, H. F. IMPY: an Improved Thioflavin-T Derivative for In Vivo Labeling of Beta-Amyloid Plaques. Brain Res. 2002, 956, 202-210.
122. Zhang, W.; Oya, S.; Kung, M. P.; Hou, C.; Maier, D. L.; Kong, H. F. F-18 Stilbenes as PET Imaging Agents for Detecting Beta-Amyloid Plaques in the Brain. J. Med. Chem. 2005, 48, 5980-5988.
123. Shimadzu, H.; Suemoto, T.; Suzuki, M.; Shiomitsu, T.; Okamura, N.; Kudo, Y.; Sawada, T. Novel Probes for Imaging Amyloid-Beta: F-18 and C-11 Labeling of 2-(4-Aminostyryl)benzoxazole Derivatives. J. Label Compd. Radiopharm. 2004, 47, 181-190.
124. Okamura, N.; Suimoto, T.; Shimadzu, H.; Suzuki, M.; Shiomitsu, T.; Akatsu, H.; Yamamoto, T.; Staufenbiel, M.; Anai, K.; Arai, H.; Sasaki, H.; Kudo, Y.; Sawada, T. Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain. J. Neurosci. 2004, 24, 2535-2541.
125. Kung, M. P.; Zhuang, Z. P.; Hou, C.; Jin, L. W.; Kung, H. F. Characterization of Radioiodinated Ligand Binding to Amyloid Beta Plaques. J. Mol. Neurosci. 2003, 20, 249-253.
126. Kung, M. P.; Hou, C.; Zhuang, Z. P.; Skovronsky, D.; Kung, H. F. Binding of Two Potential Imaging Agents Targeting Amyloid Plaques in Postmortem Brain Tissues of Patients with Alzheimer's Disease. Brain Res. 2004, 1025, 98-105.
127. Ono, M.; Wilson, A.; Nobrega, J.; Westaway, D.; Verhoff, P.; Zhuang, Z. P.; Kung, M. P.; Kung, K. F. 11C-Labeled Stilbene Derivatives as Abeta-Aggregate-Specific PET Imaging Agents for Alzheimer's Disease. Nuc. Med. Biol. 2003, 30, 565-571.
128. Mathis, C. A.; Holt, D. P.; Wang, Y.; Huang, G. F.; Debnath, M. L.; Klunk, W. E. Lipophilic 11C-Labelled Thioflavin-T Analogues for Imaging Amyloid Plaques in Alzheimer's Disease. J. Label Compd. Radiopharm. 2001, 44, S26-S28.
129. Mathis, C. A.; Bacskai, B. J.; Kajdasz, S. T.; McLellan, M. E.; Frosch, M. P.; Hyman, B. T.; Holt, D. P.; Wang, Y.; Huang, G. F.; Debnath, M. L.; Klunk, W. E. A Lipophilic Thioflavin-T Derivative for Positron Emission Tomography (PET) Imaging of Amyloid in Brain. Bioorg. Med. Chem. Lett. 2002, 12, 295-298.
130. Mathis, C. A.; Wang, Y.; Holt, D. P.; Huang, G. F.; Debnath, M. L.; Klunk, W. E. Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazole Amyloid Imaging Agents. J. Med. Chem. 2003, 46, 2740-2754.
131. Agdeppa, E. D.; Kepe, V.; Liu, J.; Flores-Torres, S.; Satyamurthy, N.; Petric, A.; Cole, G. M.; Small, G. W.; Huang, S. C.; Barrio, J. R. Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthlethylidene Derivatives as Positron Emission Tomography Imaging Probes for Beta-Amyloid Plaques in Alzheimer's Disease. J. Neurosci. 2001, 21, RC189-RC193.
132. Suemoto, T.; Okamura, N.; Shiomitsu, T.; Suzuki, M.; Shimadzu, H.; Akatsu, H.; Yamamoto, T.; Kudo, Y.; Sawada, T. In Vivo Labeling of Amyloid with BF-108. Neurosci. Res. 2004, 48, 65-74.
133. Ono, M.; Haratake, M.; Nakayama, M.; Kaneko, Y.; Kawabata, K.; Mori, H.; Kung, M. P.; Kung, H. F. Synthesis and Biological Evaluation of (E)-3-Styrylpyridine Derivatives as Amyloid Imaging Agents for Alzheimer's Disease. Nuc. Med. Biol. 2005, 32, 329-335.
134. Wang, Y.; Klunk, W. E.; Debnath, M. L.; Huang, G. F.; Holt, D. P.; Shao, L.; Mathis, C. M. Development of a PET/SPECT Agent for Amyloid Imaging in Alzheimer's Disease. J. Mol. Neurosci. 2004, 24, 55-62.
135. Wang, Y.; Mathis, C. A.; Huang, G. F.; Debnath, M. L.; Holt, D. P.; Shao, L.; Klunk, W. E. Effects of Lipophilicity on the Affinity and Nonspecific Binding of Iodinated Benzothiazole Derivatives. J. Mol. Neurosci. 2003, 20, 255-260.
136. Bacskai, B. J.; Hickey, G. A.; Skoch, J.; Kajdasz, S. T.; Wang, Y.; Huang, G. F.; Mathis, C. A.; Klunk, W. E.; Hyman, B. T. Four-Dimensional Multiphoton Imaging of Brain Entry, Amyloid Binding, and Clearance of an Amyloid-Beta Ligand in Transgenic Mice. Proc. Natl. Acad. Sci. USA 2003, 100, 12462-12467.
137. Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D. P.; Bergstrom, M.; Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausen, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.; Lopresit, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.; Langstrom, B. Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55, 306-319.
138. Thal, D. R.; Rueb, U.; Orrantes, M.; Braak, H. Phases of Abeta-Deposition in the Human Brain and its Relevance for the Development of AD. Neurology 2002, 58, 1791-1800.
139. Mark, R. J.; Pang, Z.; Geddes, J. W.; Uchida, K.; Mattson, M. P. Amyloid Beta-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation. J. Neurosci. 1997, 17, 1046-1054.
140. Mesulam, M. M. Neuroplasticity Failure in Alzheimer's Disease: Bridging the Gap between Plaques and Tangles. Neuron 1999, 24, 521-529.
141. Price, J. C.; Klunk, W. E.; Lopresti, B. J.; Lu, X.; Hoge, J. A.; Ziolko, S. K.; Holt, D. P.; Meltzer, C. C.; DeKosky, S. T.; Mathis, C. A. Kinetic Modeling of Amyloid Binding in Humans Using PET Imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 2005, 25, 1528-1547.
142. Lopresti, B. J.; Klunk, W. E.; Mathis, C. A.; Hodge, J. A.; Ziolko, S. K.; Lu, X.; Meltzer, C.; DeKosky, S. T.; Price, J. C. Simplified Quantification of PIB Amyloid Imaging PET Studies. J. Cereb. Blood Flow Metab. 2005, 25, S589.
143. Edison, P.; Archer, H.; Hinz, R.; Hammers, A.; Gerhard, A.; Pavese, N.; Tai, Y.; Hotton, G.; Cuttler, D.; Fox, N.; Rossor, M.; Brooks, D. J. Correlation of Regional Cerebral Amyloid Load in Alzheimer's Disease, Measured with [11C]-PIB PET Using Spectral Analysis and Tissue Uptake Ratios, with Performance on Recognition Memory Tests. J. Cereb. Blood Flow Metab. 2005, 25, S591.
144. Kung, H. F.; Lee, C. W.; Zhuang, Z. P.; Kung, M. P.; Hou, C.; Plossl, K. Novel Stilbenes as Probes for Amyloid Plaques. J. Am. Chem. Soc. 2001, 123, 12740-12741.
145. Verhoeff, N.; Wilson, A. A.; Takeshita, S.; Trop, L.; Hussey, D.; Singh, K.; Kung, H. F.; Kung, M. P.; Houle, S. In-Vivo Imaging of Alzheimer Disease Beta-Amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 2004, 12, 584-595.
146. Ichise, M.; Meyer, J. H.; Yonekura, Y. An Introduction to PET and SPECT Neuroreceptor Quantification Models. J. Nucl. Med. 2001, 42, 755-763.
147. Zakzanis, K. K. Statistics to Tell the Truth, the Whole Truth, and Nothing but the Truth: Formulae, Illustrative Numerical Examples, and Heuristic Interpretation of Effect Size Analyses for Neuropsychological Researchers. Arch. Clin. Neuropsychol. 2001, 16, 653-667.
148. Agdeppa, E. D.; Kepe, V.; Petric, A.; Satymurthy, N.; Liu, J.; Huang, S. C.; Small, G. W.; Cole, G. M.; Barrio, J. R. In Vitro Detection of (S)-Naproxen and Ibuprofen Binding to Plaques in the Alzheimer's Brain Using the Positron Emission Tomography Molecular Imaging Probe 2-(1-16-[{2-[18F]Fluoroethyl(methyl) amino]-2-naphthylethylidene}malonitrile. Neuroscience 2003, 117, 723-730.
149. Shoghi-Jadid, K.; Small, G. W.; Agdeppa, E. D.; Kepe, V.; Ercoli, L. M.; Siddarth, P.; Read, S.; Satyamurthy, N.; Petric, A.; Huang, S. C.; Barrio, J. R. Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of Living Patients With Alzheimer Disease. Am. J. Geriatr. Psychiatry 2002, 10, 24-35.
150. Small, G. W.; Kepe, V.; Huang, S. C.; Wu, H. M.; Ercoli, L.; Siddarth, P.; Karen, M.; Lavretsky, H.; Wright, B. C.; Shoghi-Jadid, K.; Satyamurthy, N. E.; Phelps, M. E.; Barrio, J. R. Plaque and Tangle Brain Imaging Using [F-18]FDDNP-PET Differentiates Alzheimer's Disease, Mild Cognitive Impairment, and Older Controls. Neurobiol. Aging 2004, 25, S58.
151. Ye, L.; Morgenstern, J. L.; Gee, A. D.; Hong, G.; Brown, J.; Lockhart, A. Delineation of Positron Emission Tomography Imaging Agent Binding Sites on Beta-Amyloid Peptide Fibrils. J. Biol. Chem. 2005, 280, 23599-23604.
152. Ono, M.; Yoshida, N.; Ishibashi, K.; Haratake, M.; Arano, Y.; Mori, H.; Nakayama, M. Radioiodinated Flavones for in Vivo Imaging of Beta-Amyloid Plaques in the Brain. J. Med. Chem. 2005, 48, 7253-7260.
153. Lockhart, A.; Ye, L.; Judd, D. B.; Merritt, A. T.; Lowe, P. N.; Morgenstern, J. L.; Hong, G.; Gee, A. D.; Brown, J. Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on Beta-Amyloid Peptide Fibrils. J. Biol. Chem. 2005, 280, 7677-7684.
154. Laurelle, M.; Slifstein, M.; Huang, Y. Relationships between Radiotracer Properties and Image Quality in Molecular Imaging of the Brain with Positron Emission Tomography. Mol. Imag. Biol. 2003, 5, 363-375.
155. Kung, M. P.; Hou, C.; Huang, Z. P.; Cross, A. J.; Maier, D. L.; Kung, H. F. Characterization of IMPY as a Potential Imaging Agent for Beta-Amyloid Plaques in Double Transgenic PSAPP Mice. Eur. J. Nucl. Med. Mol. Imag. 2004, 31, 1136-1145.
156. Klunk, W. E.; Lopresti, B. J.; Debnath, M. L.; Holt, D. P.; Wang, Y.; Huang, G.; Shao, L.; Lefterov, L; Koldamova, R.; Ikonomovic, M.; DeKosky, S. T.; Mathis, C. A. Amyloid Deposits in Transgenic PS1/APP Mice Do Not Bind the Amyloid PET Tracer, PIB, in the Same Manner as Human Brain Amyloid. Neurobiol. Aging 2004, 25, S232-S233.
157. Toyama, H.; Ye, D.; Ichise, M.; Liow, J. S.; Cai, L.; Jacobowitz, D.; Musachio, J. L.; Hong, J.; Crescenzo, M.; Tipre, D.; Lu, J. Q.; Zoghbi, S.; vines, D. C.; Seidel, J.; Katada, K.; Green, M. V.; Pike, V. W.; Cohen, R. M.; Innis, R. B. PET Imaging of Brain with the Beta-Amyloid Probe, [11C]6-OH-BTA-1, in a Transgenic Mouse Model of Alzheimer's Disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 593-600.
158. Kepe, V.; Cole, G. M.; Liu, J.; Flood, D. G.; Trusko, S. P.; Satyamurthy, N.; Huang, S. C.; Small, G. W.; Petric, A.; Phelps, M. E.; Barrio, J. R. In Vivo Imaging of Beta-Amyloid Load in Transgenic Rodents with [F-18]FDDNP MicroPET. J. Cereb. Blood Flow Metab. 2005, 25, S588.
159. Muir, J. L. Acetylcholine, Aging, and Alzheimer's Disease. Pharm. Biochem. Behav. 1997, 56, 687-696.
160. Shianotoh, H.; Fukushi, K.; Nagatsuka, S.; Irie, T. Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design. Curr. Pharm. Design 2004, 10, 1505-1517.
161. Rinne, J. O.; Kaasinen, V.; Jarvenpaa, T.; Nagren, K.; Roivainen, A.; Yu, M.; Oikonen, V.; Kurki, T. Brain Acetylcholinesterase Activity in Mild Cognitive Impairment and Early Alzheimer's Disease. J. Neurol. Neurosurg. Psychiatry 2003, 74, 113-115.
162. Nordberg, A. Nicotinic Receptor Abnormalities of Alzheimer's Disease: Therapeutic Implications. Biol. Psychiatry 2001, 49, 200-210.
163. Woodruff-Pak, D. S. Preclinical Experiments on Cognition Enhancement in Alzheimer's Disease: Drugs Affecting Nicotinic Acetylcholine Receptors. Drug Development Research 2002, 56, 335-346.
164. Wu, J.; Kuo, Y. P.; George, A. A.; Xu, L.; Hu, J.; Lukas, R. J. Beta-Amyloid Directly Inhibits Human Alpha4beta2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SHEP1 Cells. J. Biol. Chem. 2004, 36, 37842-37851.
165. Fujita, M.; Ichise, M.; Dyck, C. H. v.; Zoghbi, S. S.; Tamagnan, G.; Mukhin, A. G.; Bozkurt, A.; Seneca, N.; Tipre, D.; DeNucci, C. C.; Iida, H.; Vaupel, D. B.; Horti, A. G.; Koren, A. O.; Kimes, A. S.; London, E. D.; Seibyl, J. P.; Baldwin, R, M.; Innis, R. B. Quantification of Nicotinic Acetylcholine Receptors in Human Brain Using [1231]5-I-A-85380 SPET. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 1620-1629.
166. Gallezot, J. D.; Bottlaender, M.; Gregoire, M. C.; Roumenov, D.; Deverre, J. R.; Coulon, C.; Ottaviani, M.; Dolle, F.; Syrote, A.; Valette, H. In Vivo Imaging of Human Cerebral Nicotinic Acetylcholine Receptors with 2-18F-Fluoro-A-85380 and PET. J. Nucl. Med. 2005, 46, 240-147.
167. Ding, Y. S.; Fowler, J. S.; Logan, J.; Wang, G. J.; Telang, F.; Garza, V.; Biegon, A.; Pareto, D.; Rooney, W.; Shea, C.; Alexoff, D.; Volkow, N.; Vocci, F. 6-[18F]Fluoro-A-85380, a new PET Tracer for the Nicotinic Acetylcholine Receptor: Studies in the Human Brain and In Vivo Demonstration of Specific Binding in White Matter. Synapse 2004, 53, 184-189.
168. Mackenzie, I. R.; Hao, C.; Munoz, D. G. Role of Microglia in Senile Plaque Formation. Neurobiol. Aging 1995, 16, 797-804.
169. Banati, R. B.; Myers, R.; Kreutzberg, G. W. PK ('Peripheral Benzodiazepine')- Binding Sites in the CNS Indicate Early and Discrete Brain Lesions: Microautoradiographic Detection of [H-3]PK11195 Binding to Activated Microglia. J. Neurocytol. 1997, 26, 77-82.
170. Cagnin, A.; Brooks, D. J.; Kennedy, A. M.; Gunn, R. N.; Myers, R.; Turkheimer, F. E.; Jones, T.; Banati, R. B. In-Vivo Measurement of Activated Microglia in Dementia. Lancet 2001, 358, 461-467
171. Cagnin, A.; Rossor, M.; Sampson, E. L.; KacKinnon, T.; Banati, R. B. In Vivo Detection of Microglial Activation in Frontotemporal Dementia. Ann. Neurol. 2004, 56, 894-897.